Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 09877 JENSCARE-B > Detailed Quotes

09877 JENSCARE-B

Watchlist
40.850
-1.350-3.20%
Closed  01/27 16:08 CCT
High
41.400
Open
40.000
Turnover
1.74M
Low
38.200
Pre Close
42.200
Volume
43.60K
Market Cap
17.04B
P/E(TTM)
Loss
52wk High
94.700
Shares
417.17M
P/E(Static)
Loss
52wk Low
26.000
Float Cap
5.38B
Bid/Ask %
-47.37%
Historical High
94.700
Shs Float
131.59M
Volume Ratio
1.05
Historical Low
26.000
Dividend TTM
--
Div Yield TTM
--
P/B
11.54
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.03%
Amplitude
7.58%
Avg Price
39.847
Lot Size
200
Float Cap
5.38B
Bid/Ask %
-47.37%
Historical High
94.700
Shs Float
131.59M
Volume Ratio
1.05
Historical Low
26.000
Dividend TTM
--
P/B
11.54
Dividend LFY
--
Turnover Ratio
0.03%
Amplitude
7.58%
Avg Price
39.847
Lot Size
200
Price Forecast

News

Comment

No More
Company Overview More
Ningbo Jianshi Technology Co., Ltd. is a medical device company based in China, dedicated to developing interventional products for the treatment of structural heart disease. The company was established in November 2011 in China. Since then, we have developed a range of treatment solutions for different types of structural heart diseases, including tricuspid valve disease, aortic valve disease, mitral valve disease, and heart failure. Our core product, LUX-Valve, has the potential to treat severe tricuspid valve reflux, and according to Frost & Sullivan's data, since LUX-Valve is the world's first product under development to complete the enrollment of test subjects in confirmatory clinical trials, it is expected to be one of the first transcatheter tricuspid valve replacement products approved for commercialization in the world. Furthermore, according to Frost & Sullivan's data, LUX-Valve was recognized as a “breakthrough medical device” under the Breakthrough Medical Device Program by the US Food and Drug Administration in November 2021, making it the first domestic self-developed medical device in the field of valvular heart disease treatment to receive this certification. Our other core product, Ken-Valve, is designed to treat severe aortic valve reflux (or aortic stenosis combined with aortic stenosis) and is expected to meet the needs of more patients, far greater than the transcatheter aortic valve replacement system for which only treatment of aortic stenosis is indicated. We are also developing eight other products with advanced technology, including (i) JenSclip, an innovative transcatheter mitral valve repair clamping system with many unique designs that make it stand out from other transcatheter mitral valve repair systems on the market; (ii) MitraPatch, an innovative transcatheter mitral valve repair product that uses valve repair technology to repair the mitral valve; and a number of advanced products under development for different types of valvular heart disease and heart failure.
CEO: Shiwen Lv
Market: Hong Kong motherboard
Listing Date: 10/10/2022
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist